Both invasive fungal infection with Aspergillus fumigatus and blood stream infection with methicillin-susceptible Staphylococcus aureus (MSSA) have a significant incidence in the critically ill. Voriconazole and, more recently, isavuconazole and high dose flucloxacillin are the standard first line treatments for these respective serious infections. However, an underestimated risk of a significant interaction needs to be taken into consideration, when both co-occur. We wish to highlight this important issue in the management of these patients through two case reports and to point to the inconsistency between different validated databases regarding this significant interaction as well the importance of a strict protocol for readily available therapeutic drug monitoring.

烟曲霉的侵袭性真菌感染和甲氧西林敏感金黄色葡萄球菌(MSSA) 的血流感染在危重患者中的发病率很高。伏立康唑和最近的艾沙康唑和大剂量氟氯西林是这些严重感染的标准一线治疗方法。但是，当两者同时发生时，需要考虑被低估的重大交互风险。我们希望通过两份病例报告强调这些患者管理中的这一重要问题，并指出不同经过验证的数据库之间关于这种重要相互作用的不一致，以及对现成的治疗药物监测制定严格协议的重要性。